U.S. markets closed
  • S&P 500

    4,274.04
    -31.16 (-0.72%)
     
  • Dow 30

    33,980.32
    -171.69 (-0.50%)
     
  • Nasdaq

    12,938.12
    -164.43 (-1.25%)
     
  • Russell 2000

    1,987.31
    -33.22 (-1.64%)
     
  • Crude Oil

    87.29
    +0.76 (+0.88%)
     
  • Gold

    1,776.30
    -13.40 (-0.75%)
     
  • Silver

    19.74
    -0.35 (-1.74%)
     
  • EUR/USD

    1.0181
    +0.0010 (+0.10%)
     
  • 10-Yr Bond

    2.8930
    +0.0690 (+2.44%)
     
  • GBP/USD

    1.2052
    -0.0043 (-0.35%)
     
  • USD/JPY

    135.0500
    +0.8350 (+0.62%)
     
  • BTC-USD

    23,371.21
    -586.83 (-2.45%)
     
  • CMC Crypto 200

    557.23
    -15.58 (-2.72%)
     
  • FTSE 100

    7,515.75
    -20.31 (-0.27%)
     
  • Nikkei 225

    29,222.77
    +353.86 (+1.23%)
     

COVID vaccine’s FDA approval and next steps: Novavax CEO

Novavax CEO Stanley Erck remarks on the FDA’s Covid vaccine approval, and the potential next steps. Segment originally aired on July 21, 2022.

Video Transcript

STANLEY ERCK: So it's been a big week, obviously, with EUA, with FDA approval of our doses that we've shipped to the United States. It'll be available to the public by sometime during the week next week. What we're also working on is what our approval for-- was for, people who hadn't been vaccinated before and adults over 18.

The next approval, we think, will come in the next week or two. Will expand down to adolescents from 12 to 18 years old, and then subsequently expand that for boosters, so that you can boost any vaccine with our vaccine. We have an opportunity that the FDA could take the approach that Europe, Australia, and Japan have done, which is to recommend it for boosting right away.

They might wait for more data. And if so, it'll be more toward the end of the summer. We have global manufacturing capacity. We'll be making not only the current vaccine, but we'll be looking to make the Omicron vaccine if it's necessary.